Natural Killer Cell Immunotherapy After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia Patients: Phase I Clinical Trial.

Authors

Shiva Eskandarian, Amirhossein Izadpanah, Saye Parkhideh, Mahshid Mehdizade, Sahar Parkhideh, Mozhdeh Mohammadian, Mehrshad Seresht-Ahmadi, Mehdi Bakhtiyaridovvombaygi, Abdollah Sabri, Ahmad Gharehbaghian, Abbas Hajifathali, Elham Roshandel

Published in

Stem cell reviews and reports. Aug 03, 2026. Epub Aug 03, 2026.

Abstract

Immunotherapy offers a promising approach to prevent relapse and transplant complications. Natural killer (NK) cells play a crucial role in the immune system's initial defense against infections and malignant cells. Activation of NK cells with interleukin-15 enhances anti-leukemic immune responses. We conducted this clinical trial to evaluate the safety and efficacy of CD56 + cell infusion in increasing survival and reducing relapse in patients with acute myeloid leukemia.
Three escalating doses of 1 × 10⁶, 3 × 10⁶, and 5 × 10⁶ interleukin-15-activated CD56 + cells/kg derived from peripheral blood of haploidentical donors were injected on days + 7, +14, and + 21 following transplantation. Patients were monitored for adverse events. To evaluate efficacy, bone marrow samples were taken on days + 30 and + 90. On day + 40, the population of NK cells and its correlation with patients' clinical status were evaluated. Besides, immune reconstitution was examined on day + 40. Patients were followed up for one year.
The CD56 + cells infusion was safe and not associated with any complications. While survival rates were not statistically different between the intervention and control groups, a trend toward improved survival was observed in the intervention group. Patients with complete remission showed a higher percentage of NK cells on day + 40 than patients who experienced graft rejection, relapse, or death.
In this study, we introduce a feasible method for activating CD56 + cells. Although the survival rates of patients in the intervention and control groups did not differ statistically, this study showed that a higher percentage of NK cells on day + 40 is associated with better survival and fewer complications following transplantation.
This study was registered at the Iranian Registry of Clinical Trials under code IRCT20230801058996N2 on 2023-09-10.

PMID:
42545587
Bibliographic data and abstract were imported from PubMed on 03 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.